Date: 2013-12-18
Type of information: Licensing agreement
Compound: OmniRat platform
Company: Open Monoclonal Technology (USA) Roche (Switzerland) Genentech, a member of the Roche Group (USA - Switzerland)
Therapeutic area: Technology - Services
Type agreement:
Action mechanism: OmniRat® is a fully human monoclonal antibody platform based on rats.
Disease:
Details: * On December 18, 2013, Open Monoclonal Technology has announced that Genentech, a member of the Roche Group, and Roche will acquire unlimited access to OmniRat® through the purchase of one of OMT’s spinout companies. Following the acquisition, Genentech and Roche will be able to use the platform to generate human therapeutic antibodies for any target and indication. Genentech and Roche also gained the right to further engineer the antibody platform.
Financial terms:
Latest news:
